Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site

References

• Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012;491:364–73
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85–95
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012;21:297–308
   PubMed Web of Science ®Google Scholar
• Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 2015;11:9–15
   PubMed Web of Science ®Google Scholar
• Kim J, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927–30
   PubMed Web of Science ®Google Scholar
• Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177–85
   PubMed Web of Science ®Google Scholar
• Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37–51
   PubMed Web of Science ®Google Scholar
• Patel MS, Nemeria NS, Furey W, Jordan F. The pyruvate dehydrogenase complexes: structure-based function and regulation. J Biol Chem 2014;289:16615–23
   PubMed Web of Science ®Google Scholar
• Roche TE, Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell Mol Life Sci 2007;64:830–49
   PubMed Web of Science ®Google Scholar
• Knoechel TR, Tucker AD, Robinson CM, et al. Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry 2006;45:402–15
   PubMed Web of Science ®Google Scholar
• Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 2007;15:992–1004
   PubMed Web of Science ®Google Scholar
• Li J, Kato M, Chuang DT. Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate. J Biol Chem 2009;284:34458–67
   PubMed Web of Science ®Google Scholar
• Kukimoto-Niino M, Tokmakov A, Terada T, et al. Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4. Acta Crystallogr D Biol Crystallogr 2011;67:763–73
   PubMedGoogle Scholar
• Tso S-C, Qi X, Gui W-J, et al. Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket. J Biol Chem 2014;289:4432–43
   PubMed Web of Science ®Google Scholar
• Moore JD, Staniszewska A, Shaw T, et al. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget 2014;5:12862–76
   PubMed Web of Science ®Google Scholar
• Mann WR, Dragland CJ, Vinluan CC, et al. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors. Biochim Biophys Acta 2000;1480:283–92
   PubMed Web of Science ®Google Scholar
• Xie Q, Zhang H-F, Guo Y-Z, et al. Combination of Taxol® and dichloroacetate results in synergistically inhibitory effects on Taxol-resistant oral cancer cells under hypoxia. Mol Med Rep 2015;11:2935–40
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:31–4
   Google Scholar
• Brandsma D, Dorlo TPC, Haanen JH, et al. Severe encephalopathy and polyneuropathy induced by dichloroacetate. J Neurol 2010;257:2099–100
   PubMed Web of Science ®Google Scholar
• Stockwin LH, Yu SX, Borgel S, et al. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer 2010;127:2510–19
   PubMed Web of Science ®Google Scholar
• Pomerantz M, Yang H, Cheng Y. Poly(alkyl thiophene-3-carboxylates). Synthesis and characterization of polythiophenes with a carbonyl group directly attached to the ring. Macromolecules 1995;28:5706–8
   Web of Science ®Google Scholar
• Schnute ME, Brideau RJ, Collier SA, et al. Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition. Bioorg Med Chem Lett 2008;18:3856
   PubMed Web of Science ®Google Scholar
• Obrecht D, Ermert P, Oumouch S, et al. Conformationally constrained, fully synthetic macrocyclic compounds. International Patent Application WO/2011/014973, 2011; Polyphor AG
   Google Scholar
• Schmidt MW, Baldridge KK, Boatz JA, et al. General atomic and molecular electronic structure system. J Comput Chem 1993;14:1347–63
   Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010;31:455–61
   PubMed Web of Science ®Google Scholar
• Korth M. Third-generation hydrogen-bonding corrections for semiempirical QM methods and force fields. J Chem Theory Comput 2010;6:3808–16
   Web of Science ®Google Scholar
• Dobeš P, Řezáč J, Fanfrlík J, et al. Semiempirical quantum mechanical method PM6-DH2X describes the geometry and energetics of CK2-inhibitor complexes involving halogen bonds well, while the empirical potential fails. J Phys Chem B 2011;115:8581–9
   PubMed Web of Science ®Google Scholar
• Stewart JJP. MOPAC2012 [Internet]. Colorado Springs, CO, USA: Stewart Computational Chemistry; 2012. Available from: http://OpenMOPAC.net
   Google Scholar
• Petitjean M. On the analytical calculation of van der Waals surfaces and volumes: some numerical aspects. J Comput Chem 1994;15:507–23
   Web of Science ®Google Scholar
• Mantina M, Chamberlin AC, Valero R, et al. Consistent van der Waals radii for the whole main group. J Phys Chem A 2009;113:5806–12
   PubMed Web of Science ®Google Scholar
• Korotchkina LG, Patel MS. Mutagenesis studies of the phosphorylation sites of recombinant human pyruvate dehydrogenase. Site-specific regulation. J Biol Chem 1995;270:14297–304
   PubMed Web of Science ®Google Scholar
• Liu TC, Korotchkina LG, Hyatt SL, et al. Spectroscopic studies of the characterization of recombinant human dihydrolipoamide dehydrogenase and its site-directed mutants. J Biol Chem 1995;270:15545–50
   PubMed Web of Science ®Google Scholar
• Yang D, Song J, Wagenknecht T, Roche TE. Assembly and full functionality of recombinantly expressed dihydrolipoyl acetyltransferase component of the human pyruvate dehydrogenase complex. J Biol Chem 1997;272:6361–9
   PubMed Web of Science ®Google Scholar
• Korotchkina LG, Patel MS. Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites. J Biol Chem 2001;276:5731–8
   PubMed Web of Science ®Google Scholar
• Bowker-Kinley MM, Davis WI, Wu P, et al. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998;329:191–6
   PubMed Web of Science ®Google Scholar
• Wierckx N, Koopman F, Ruijssenaars HJ, de Winde JH. Microbial degradation of furanic compounds: biochemistry, genetics, and impact. Appl Microbiol Biotechnol 2011;92:1095–105
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Keserü GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 2014;13:105–21
   PubMed Web of Science ®Google Scholar